Unaudited Standalone & consolidated Financial Result of the company for the quarter & half year ended 30th September 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and in line with its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Genpharmasec Limited reported a sharp jump in standalone revenue to Rs 3,456.57 lakhs in Q2 FY26 from Rs 766.95 lakhs in Q2 FY25, with H1 FY26 standalone revenue at Rs 4,467.68 lakhs versus Rs 1,107.24 lakhs a year ago. Standalone profit after tax for H1 FY26 rose to Rs 237.51 lakhs from Rs 158.64 lakhs, a roughly 50% increase. Consolidated H1 FY26 PAT was almost flat at Rs 3.91 lakhs as the newly acquired Derren Healthcare subsidiary (70% stake completed July 25, 2025) reported a loss of Rs 171.60 lakhs since acquisition. Q2 FY26 standalone PBT was Rs 138.06 lakhs; consolidated Q2 FY26 slipped into a loss of Rs 117.62 lakhs. The company also changed its accounting policy, reclassifying certain equity shares from inventories to FVOCI investments, applied retrospectively.
Standalone growth is strong and likely stock-positive, but the consolidated picture is dragged down by the newly consolidated Derren Healthcare losses, and shareholders should note the mid-year auditor change (Bilimoria Mehta & Co replacing the previous auditor) along with sharply higher trade payables and borrowings on the balance sheet.